---
title: "VK2735 in Chronic weight management: Dual GIP and GLP-1 receptor agonists"
description: "Formulary evidence on VK2735 in Chronic weight management: Dual GIP and GLP-1 receptor agonists. Topics: Tirzepatide: FDA-approved indications, Tirzepatide: dosage escalation and maintenance dosages, Tirzepatide: three-year weight change and progression to type 2 diabetes in participants with prediabetes, Tirzepatide: apnea-hypopnea index in moderate-to-severe obstructive sleep apnea in SURMOUNT-OSA, and 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/dual-gip-and-glp-1-receptor-agonists"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Dual GIP and GLP-1 receptor agonists

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Dual GIP and GLP-1 Receptor Agonists

<a id="topic-2.2.2.1.3-1"></a>

### Tirzepatide: FDA-approved indications

> “ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity:”
> “to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.”
> “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.”
> “Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

<a id="topic-2.2.2.1.3-2"></a>

### Tirzepatide: dosage escalation and maintenance dosages

> “The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks.”
> “After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose”
> “The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”
> “The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

<a id="topic-2.2.2.1.3-3"></a>

### Tirzepatide: three-year weight change and progression to type 2 diabetes in participants with prediabetes

> “At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo).”
> “Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001).”

Source: [Jastreboff et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39536238/)

<a id="topic-2.2.2.1.3-4"></a>

### Tirzepatide: apnea-hypopnea index in moderate-to-severe obstructive sleep apnea in SURMOUNT-OSA

> “In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).”
> “In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.2.2.1.3-5"></a>

### Tirzepatide: oral hormonal contraceptive counseling in the American Diabetes Association 2026 Standards of Care

> “Tirzepatide in particular may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying, an effect that is largest after the first dose and diminishes over time.”
> “Individuals using oral hormonal contraceptives should switch to a nonoral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.3-6"></a>

### Tirzepatide: self-pay price for the KwikPen and single-dose vial

> “Zepbound patients can access all doses in either multi-dose KwikPen or single-dose vial at the same self-pay price, starting at $299, available by prescription now through LillyDirect”
> “INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device.”
> “The price of Zepbound is the same for both KwikPen and single-dose vials with Zepbound Self Pay Journey Program.”

Source: [Eli Lilly Zepbound KwikPen announcement (2026)](https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management)

<a id="topic-2.2.2.1.3-7"></a>

### Tirzepatide: average wholesale price and National Average Drug Acquisition Cost

| Medication | Typical adult maintenance dose | AWP for 30-day supply | NADAC for 30-day supply |
| --- | --- | --- | --- |
| Tirzepatide | “5, 10, or 15 mg once weekly” | “$1,304” | “$1,022” |

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

Additional sources: [Eli Lilly Zepbound pricing information (2026)](https://www.lillypricinginfo.com/zepbound); [Eli Lilly Zepbound coverage and savings (2026)](https://zepbound.lilly.com/hcp/coverage-savings)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
